The Career and Accomplishments of JeanMarie Guenot

JeanMarie Guenot is President and CEO of Amphivena Therapeutics. She has goals and aspirations for the business and pharmaceutical fields, with an emphasis on creating drugs to treat cancer patients in the most effective way possible. With over 20 years of experience in the industry as a business administrator, she has made many contributions in the pharmaceutical field, by working with companies at all levels on linkedin.com.

JeanMarie Guenot began her career at Atlas Ventures. It was there that she built and managed life science companies. She was also employed by Hoffmann-La Roche, where she developed autoimmune disease drugs. Her focus is in quantum mechanical and semi empirical methods for molecular dynamics, protein structure prediction, and drug design. With a passion for combining the fields of business and pharmaceuticals, Dr. Guenot earned her MBA from the Wharton School at the University of Pennsylvania and her Ph.D. from University of California, San Fransisco.

JeanMarie’s dedication and hard work have been featured in the media outlet CrunchBase. Her LinkedIn page also outlines her cancer research efforts, as well as her specialization in drug design.

Dr. Jeanmarie Guenot is the founder of SKS Ocular, which is a start-up opthalmic company. Her portfolio, project and alliance management experience includes cardiovascular disease, neurology, and opthalmic diseases.

One of Dr. Geunot’s goals is to change cancer therapy. She would like to develop a drug that targets cancer cells with minimal side effects for the patient. She feels that the way to do this is by engaging the body’s own T-cells, and develop a new drug within 5 years.

During her career, Dr. Guenot has made significant accomplishments in her field of research at http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/. She managed profits and losses, mergers and acquisitions. She licensed Opthotec for the opthalmic indication on the oncology drug, and collaborated between two companies for three phase 2 cancer patients.